In adults with acute necrotising pancreatitis and baseline ALC of at least 0.8 x 10^9/L, thymosin alpha‑1 reduced the risk of infected pancreatic necrosis versus placebo.
In plain wordsIn adults with acute necrotising pancreatitis and a higher lymphocyte count, thymosin alpha‑1 lowered the risk of infected pancreatic necrosis compared with placebo.
- Peptide
- Thymosin alpha-1
- Outcome
- DecreaseInfected pancreatic necrosis, baseline ALC 0.8 x 10^9/L or higher
- Study
n = 290
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Infection and antimicrobial activity · Infection
- Studied dose
- 1.6 mg every 12 h for the first 7 days, then 1.6 mg once a day for 7 days · subcutaneous · 14 daysAs given in this study (human).
Measurements
- Covariate-adjusted risk difference
- −0.12 risk difference
- baseline ALC >=0.8 x 10^9/L
Source sentences
Within the subgroup of patients with baseline ALC≥0.8 × 10ˆ9/L (n = 290), the Tα1 therapy significantly reduced the risk of IPN (covariate adjusted risk difference, -0.12; 95% CI, -0.21,-0.02; p = 0.015).
2 context sentences(design, population, supporting numbers)
A post-hoc analysis of data from a multicentre, double-blind, randomised, placebo-controlled trial testing the efficacy of Tα1 therapy in patients with predicted severe ANP was performed.
Patients from 16 hospitals of China were randomised to receive a subcutaneous injection of Tα1 1.6 mg every 12 h for the frst 7 days and 1.6 mg once a day for the following 7 days or a matching placebo during the same period.